Talabostat : Point Therapeutics : DPP inhibitor

Clinical Development - Talabostat in Lung Cancer (Point Therapeutics)
Describes results of a phase II trial of talabostat in patients with advanced lung cancer. A phase III trial is planned.

Talabostat - Clinical Trials (ClinicalTrials.gov)